Greater Boston is the global epicenter of life science innovation — world-class research institutions, venture capital, entrepreneurs, and pharma all within one collaborative ecosystem. Local investors discuss what makes it work, emerging trends, and how founders can plug into one of the deepest pools of life science capital anywhere.

Health systems are increasingly vital partners for early-stage healthcare companies — as clinical collaborators, pilot sites, customers, and investors. This panel covers how startups build productive relationships with hospitals and integrated delivery networks, including pilot programs, procurement challenges, and evidence generation.

Venture capital remains the primary source of funding for breakthrough therapeutic innovation. This panel brings together VCs actively investing from company formation through Series A, focused on scientific diligence, milestone planning, and what separates the most compelling therapeutic startups from the rest.

Large pharmaceutical companies continue to expand their reliance on external innovation, partnering with startups earlier through research collaborations, option-to-license agreements, and strategic investments. This panel explores how pharma identifies emerging technology and how founders can position for successful BD conversations.

Corporate venture groups have become key participants in healthcare investing, offering capital, strategic expertise, and commercial networks with a longer-term lens than traditional VCs. This panel examines how CVCs evaluate opportunities and how founders can maximize value from strategic investors.

Chronic diseases account for the majority of healthcare spending worldwide, creating enormous demand for innovative solutions that improve outcomes while reducing long-term costs. This panel explores where investors see the greatest opportunities across chronic disease management — emerging technologies, evolving reimbursement models, and what early-stage companies must demonstrate to attract investment in one of healthcare’s largest and fastest-growing markets.

Family offices have moved well beyond passive investing, with many now leading rounds, syndicating deals, and building dedicated venture strategies. This panel explores what differentiates family offices from traditional VC and how startups can engage this fast-growing capital source.

For many startups, the most important investment isn’t the biggest – it’s the first. Early investors provide the capital, validation, and momentum that help companies reach their first institutional financing and beyond.

This panel brings together experienced early-stage investors to discuss how they evaluate opportunities before traditional venture rounds. Panelists will explore the qualities they seek in founders, the milestones that create conviction, and how startups can successfully navigate the earliest stages of fundraising.

Women’s health is emerging as one of the most exciting investment categories, driven by growing recognition of historically underserved conditions and expanding scientific innovation. This panel covers where capital is flowing across reproductive health, menopause, oncology, and more.

Impact investing is an increasingly important capital source for companies tackling major healthcare challenges. This panel examines how impact investors measure outcomes beyond financial performance and identify opportunities to improve access, affordability, and equity while creating long-term value.